Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience.
Simple Summary: Pancreatic cancer is a serious disease with different outcomes depending on whether the tumor is in the head or the body/tail of the pancreas. This study explores why these differences exist and how they affect patients' survival when treated with standard chemotherapy. By analyzing...
| Publicado en: | Cancers Vol. 17; no. 11; pp. 1777 - 1791 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
MDPI
Jun2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=185869438&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 185869438 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726694 B74B jtl: Cancers issn: 20726694 maglogo: N pubinfo: dt: Jun2025 vid: 17 iid: 11 pid: 97109 pub: MDPI artinfo: ui: 185869438 185869438 185869438 10.3390/cancers17111777 185869438 ppf: 1777 ppct: 14 formats: tig: atl: Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience. aug: au: Esmail, Abdullah Dhillon, Vikram Al-Najjar, Ebtesam Khasawneh, Bayan Alghamdi, Mohammed Ibnshamsah, Fahad Abdelrahim, Maen affil: Section of GI Oncology, Department of Medicine, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA sug: subj: Pancreatic Neoplasms Drug Therapy Antineoplastic Agents, Combined Therapeutic Use Chemotherapy, Cancer Treatment Outcomes Pancreatic Neoplasms Prognosis Human Male Female Adult Middle Age Aged Aged, 80 and Over Texas Retrospective Design Record Review Electronic Health Records Prospective Studies Cancer Patients Survival Analysis Gemcitabine Therapeutic Use Paclitaxel Therapeutic Use Neoplasm Staging Overall Survival Progression-Free Survival Kaplan-Meier Estimator Cox Proportional Hazards Model Structural Equation Modeling Latent Structure Analysis Comparative Studies Descriptive Statistics Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Male Female ab: Simple Summary: Pancreatic cancer is a serious disease with different outcomes depending on whether the tumor is in the head or the body/tail of the pancreas. This study explores why these differences exist and how they affect patients' survival when treated with standard chemotherapy. By analyzing data from over 600 patients, the researchers aim to understand which treatments work best for each tumor location and identify patient groups with unique characteristics that could guide personalized care. This work may also encourage other researchers to explore tailored approaches for this challenging disease, advancing care strategies for better patient outcomes. Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits variable survival outcomes based on tumor location, with pancreatic head cancer (PHC) and pancreatic body/tail cancer (PBTC) differing in prognosis and treatment response. This study investigates the correlation between tumor location and survival outcomes in PDAC patients treated with standard chemotherapy regimens. Methods: A retrospective analysis of 604 PDAC patients (400 PHC, 204 PBTC) diagnosed between January 2015 and May 2024 at Houston Methodist Neal Cancer Center was conducted. Patients received either mFOLFIRINOX or gemcitabine/nab-paclitaxel as first-line therapy. Clinical data, including demographics, tumor stage, treatment modalities, and molecular profiles, were extracted from electronic records. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier analyses and Cox proportional hazards models. Latent class analysis (LCA) identified patient subgroups based on shared clinical, demographic, and survival characteristics. Results: PHC patients demonstrated superior median OS (12 months) compared to PBTC (9 months, p = 0.012) and PFS (8 months vs. 5 months, p = 0.0008). Across both subtypes, mFOLFIRINOX was associated with significantly longer OS than gem/nab-paclitaxel (PHC: 18.8 vs. 12.7 months, p < 0.0001; PBTC: 14 vs. 6 months, p = 0.011). LCA revealed distinct clusters: in PHC, a curative-intent class (median OS > 24 months) contrasted with a palliative class (<6 months); in PBTC, an aggressive treatment class (median OS > 18 months) differed from a limited treatment class (<6 months). Cluster differences were linked to treatment intensity, stage, and radiation use. Conclusions: PHC is associated with better survival outcomes than PBTC, with mFOLFIRINOX outperforming gem/nab-paclitaxel in both subtypes. LCA highlights heterogeneous patient subgroups, suggesting opportunities for personalized treatment strategies in PDAC management. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|